• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用扫频源光学相干断层扫描技术对类淋巴清除系统中淀粉样β肽过载诱导的脑血管损伤进行表征。

characterization of cerebrovascular impairment induced by amyloid β peptide overload in glymphatic clearance system using swept-source optical coherence tomography.

作者信息

Yu Yao, Zhang Ning, Xiang Ben, Ding Ning, Liu Jian, Huang Jiangmei, Zhao Min, Zhao Yuqian, Wang Yi, Ma Zhenhe

机构信息

Northeastern University at Qinhuangdao, School of Control Engineering, Qinhuangdao, China.

Hebei Key Laboratory of Micro-Nano Precision Optical Sensing and Measurement Technology, Qinhuangdao, China.

出版信息

Neurophotonics. 2023 Jan;10(1):015005. doi: 10.1117/1.NPh.10.1.015005. Epub 2023 Feb 16.

DOI:10.1117/1.NPh.10.1.015005
PMID:36817752
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9933996/
Abstract

SIGNIFICANCE

Antiamyloid ( ) immunotherapy is a promising therapeutic strategy for Alzheimer's disease (AD) but generates large amounts of soluble peptides that could overwhelm the clearance pathway, leading to serious side effects. Direct implications of in glymphatic drainage transport for cerebral vasculature and tissue are not well known. Studies are needed to resolve this issue and pave the way to better monitoring abnormal vascular events that may occur in -modifying therapies for AD.

AIM

The objective is to characterize the modification of cerebral vasculature and tissue induced by soluble abundantly present in the glymphatic clearance system.

APPROACH

peptide was injected intracerebroventricularly and swept-source optical coherence tomography (SS-OCT) was used to monitor the progression of changes in the brain microvascular network and tissue over 14 days. Parameters reflecting vascular morphology and structure as well as tissue status were quantified and compared before treatment.

RESULTS

Vascular perfusion density, vessel length, and branch density decreased sharply and persistently following peptide administration. In comparison, vascular average diameter and vascular tortuosity were moderately increased at the late stage of monitoring. Endpoint density gradually increased, and the global optical attenuation coefficient value decreased significantly over time.

CONCLUSIONS

burden in the glymphatic system directly contributes to cerebrovascular structural and morphological abnormalities and global brain tissue damage, suggesting severe deleterious properties of soluble cerebrospinal fluid- . We also show that OCT can be used as an effective tool to monitor cerebrovascular dynamics and tissue property changes in response to therapeutic treatments in drug discovery research.

摘要

意义

抗淀粉样蛋白( )免疫疗法是治疗阿尔茨海默病(AD)的一种有前景的治疗策略,但会产生大量可溶性 肽,这可能会超出清除途径的负荷,导致严重的副作用。 在脑淋巴引流运输中对脑血管和组织的直接影响尚不清楚。需要开展研究来解决这一问题,并为更好地监测AD的 修饰疗法中可能发生的异常血管事件铺平道路。

目的

目的是表征脑淋巴清除系统中大量存在的可溶性 对脑血管和组织的修饰作用。

方法

将 肽脑室内注射,并使用扫频光学相干断层扫描(SS-OCT)监测14天内脑微血管网络和组织变化的进展。对反映血管形态和结构以及组织状态的参数进行量化,并与治疗前进行比较。

结果

给予 肽后,血管灌注密度、血管长度和分支密度急剧且持续下降。相比之下,在监测后期血管平均直径和血管迂曲度适度增加。端点密度逐渐增加,整体光学衰减系数值随时间显著下降。

结论

脑淋巴系统中的 负荷直接导致脑血管结构和形态异常以及全脑组织损伤,表明可溶性脑脊液 具有严重的有害特性。我们还表明,在药物发现研究中,OCT可作为监测治疗反应中脑血管动力学和组织特性变化的有效工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/b52e041ca55e/NPh-010-015005-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/71872e521f00/NPh-010-015005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/7272a3d2c1a6/NPh-010-015005-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/26e0771bbe6a/NPh-010-015005-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/d6c61d612f08/NPh-010-015005-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/5eada9b72f37/NPh-010-015005-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/27982281dac0/NPh-010-015005-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/1d65a6d95b0e/NPh-010-015005-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/b52e041ca55e/NPh-010-015005-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/71872e521f00/NPh-010-015005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/7272a3d2c1a6/NPh-010-015005-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/26e0771bbe6a/NPh-010-015005-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/d6c61d612f08/NPh-010-015005-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/5eada9b72f37/NPh-010-015005-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/27982281dac0/NPh-010-015005-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/1d65a6d95b0e/NPh-010-015005-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5df/9933996/b52e041ca55e/NPh-010-015005-g008.jpg

相似文献

1
characterization of cerebrovascular impairment induced by amyloid β peptide overload in glymphatic clearance system using swept-source optical coherence tomography.使用扫频源光学相干断层扫描技术对类淋巴清除系统中淀粉样β肽过载诱导的脑血管损伤进行表征。
Neurophotonics. 2023 Jan;10(1):015005. doi: 10.1117/1.NPh.10.1.015005. Epub 2023 Feb 16.
2
Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease.阿尔茨海默病小鼠模型中类淋巴液运输的抑制
Neurobiol Dis. 2016 Sep;93:215-25. doi: 10.1016/j.nbd.2016.05.015. Epub 2016 May 24.
3
Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis.淀粉样变性的成熟 Tet-off APP 小鼠模型中糖质分解液流动力学的改变。
Alzheimers Res Ther. 2023 Jan 28;15(1):23. doi: 10.1186/s13195-023-01175-z.
4
Photobiomodulation Therapy and the Glymphatic System: Promising Applications for Augmenting the Brain Lymphatic Drainage System.光生物调节疗法与脑淋巴系统:增强大脑淋巴引流系统的有前途的应用。
Int J Mol Sci. 2022 Mar 10;23(6):2975. doi: 10.3390/ijms23062975.
5
Impaired Glymphatic Transport in Spontaneously Hypertensive Rats.自发性高血压大鼠的糖质分解液转运功能受损。
J Neurosci. 2019 Aug 7;39(32):6365-6377. doi: 10.1523/JNEUROSCI.1974-18.2019. Epub 2019 Jun 17.
6
Alzheimer's disease brain tissue investigation: a multiscale approach using 1060-nm swept source optical coherence tomography for a direct correlation to histology.阿尔茨海默病脑组织研究:一种使用1060纳米扫频源光学相干断层扫描的多尺度方法,用于与组织学进行直接关联。
Neurophotonics. 2020 Jul;7(3):035004. doi: 10.1117/1.NPh.7.3.035004. Epub 2020 Aug 21.
7
Cerebral edema detection after middle cerebral artery occlusion using swept-source optical coherence tomography.使用扫频源光学相干断层扫描术检测大脑中动脉闭塞后的脑水肿
Neurophotonics. 2019 Oct;6(4):045007. doi: 10.1117/1.NPh.6.4.045007. Epub 2019 Nov 7.
8
Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer's disease mouse model with suppression of glymphatic clearance.小胶质细胞通过抑制神经胶质淋巴清除来防止阿尔茨海默病小鼠模型早期β-淀粉样斑块的形成。
Alzheimers Res Ther. 2020 Oct 2;12(1):125. doi: 10.1186/s13195-020-00688-1.
9
Electroacupuncture Improves Clearance of Amyloid- through the Glymphatic System in the SAMP8 Mouse Model of Alzheimer's Disease.电针对阿尔茨海默病 SAMP8 小鼠模型中淀粉样蛋白清除的影响-通过神经淋巴系统。
Neural Plast. 2021 Aug 26;2021:9960304. doi: 10.1155/2021/9960304. eCollection 2021.
10
The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases.神经血管、血脑屏障和糖脂代谢功能障碍在神经退行性和代谢性疾病中的作用。
Int Rev Neurobiol. 2020;154:413-436. doi: 10.1016/bs.irn.2020.02.006. Epub 2020 Jul 14.

引用本文的文献

1
OCT-PAM dual-mode imaging to evaluate early ischemic stroke in rats.光学相干断层扫描-光声双模态成像评估大鼠早期缺血性脑卒中
J Cereb Blood Flow Metab. 2025 Aug 20:271678X251369613. doi: 10.1177/0271678X251369613.
2
Unchanged Early Diffusion Tensor Imaging Along Perivascular Space Index After Amyloid-Targeting Disease-Modifying Therapy in Alzheimer's Disease: A Preliminary Study.阿尔茨海默病淀粉样蛋白靶向疾病修饰治疗后沿血管周围间隙指数的早期扩散张量成像无变化:一项初步研究。
medRxiv. 2025 May 9:2025.05.08.25327118. doi: 10.1101/2025.05.08.25327118.
3
Optical attenuation coefficient decorrelation-based optical coherence tomography angiography for microvascular evaluation of Alzheimer's disease on mice.

本文引用的文献

1
The glymphatic system: implications for drugs for central nervous system diseases.糖酵解系统:对中枢神经系统疾病药物的影响。
Nat Rev Drug Discov. 2022 Oct;21(10):763-779. doi: 10.1038/s41573-022-00500-9. Epub 2022 Aug 10.
2
γ-Secretase in Alzheimer's disease.γ-分泌酶在阿尔茨海默病中的作用。
Exp Mol Med. 2022 Apr;54(4):433-446. doi: 10.1038/s12276-022-00754-8. Epub 2022 Apr 8.
3
Decreased CSF clearance and increased brain amyloid in Alzheimer's disease.阿尔茨海默病患者脑脊液清除率降低和脑淀粉样蛋白增加。
基于光学衰减系数去相关的光学相干断层扫描血管造影术用于小鼠阿尔茨海默病微血管评估
Neurophotonics. 2025 Jan;12(1):015013. doi: 10.1117/1.NPh.12.1.015013. Epub 2025 Mar 12.
4
Optical coherence tomography (OCT) and OCT angiography: Technological development and applications in brain science.光学相干断层扫描(OCT)与OCT血管造影:技术发展及其在脑科学中的应用
Theranostics. 2025 Jan 1;15(1):122-140. doi: 10.7150/thno.97192. eCollection 2025.
5
Early Diabetic Retinopathy Evaluation With OCTA: A Study on Vascular Branching and Fragmentation.光学相干断层扫描血管造影术对早期糖尿病视网膜病变的评估:血管分支与血管断裂的研究
Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):21. doi: 10.1167/iovs.65.14.21.
6
Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model.糖酵解抑制加剧阿尔茨海默病模型中的 tau 蛋白传播。
Alzheimers Res Ther. 2024 Apr 5;16(1):71. doi: 10.1186/s13195-024-01439-2.
Fluids Barriers CNS. 2022 Mar 14;19(1):21. doi: 10.1186/s12987-022-00318-y.
4
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.阿尔茨海默病中的淀粉样蛋白假说:新疗法的新见解。
Nat Rev Drug Discov. 2022 Apr;21(4):306-318. doi: 10.1038/s41573-022-00391-w. Epub 2022 Feb 17.
5
Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.淀粉样蛋白相关成像异常与β淀粉样蛋白靶向抗体:一项系统综述。
JAMA Neurol. 2022 Mar 1;79(3):291-304. doi: 10.1001/jamaneurol.2021.5205.
6
High-resolution mapping of brain vasculature and its impairment in the hippocampus of Alzheimer's disease mice.阿尔茨海默病小鼠海马体中脑脉管系统的高分辨率图谱及其损伤情况
Natl Sci Rev. 2019 Nov;6(6):1223-1238. doi: 10.1093/nsr/nwz124. Epub 2019 Aug 28.
7
Revisiting FDA Approval of Aducanumab.重新审视阿杜卡努单抗的美国食品药品监督管理局批准情况。
N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.
8
Aducanumab for Alzheimer's disease?阿杜卡奴单抗治疗阿尔茨海默病?
BMJ. 2021 Jul 5;374:n1682. doi: 10.1136/bmj.n1682.
9
Three FDA advisory panel members resign over approval of Alzheimer's drug.三名美国食品药品监督管理局(FDA)咨询小组成员因阿尔茨海默病药物获批而辞职。
BMJ. 2021 Jun 11;373:n1503. doi: 10.1136/bmj.n1503.
10
Alzheimer's disease drug development pipeline: 2021.2021年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2021 May 25;7(1):e12179. doi: 10.1002/trc2.12179. eCollection 2021.